Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

CDK13-related disorder: a deep characterization of speech and language abilities and addition of 33 novel cases

European Journal of Human Genetics volume 31, pages 793–804 (2023)Cite this article

Subjects

A Correction to this article was published on 08 December 2023

This article has been updated

Abstract

Speech and language impairments are central features of CDK13-related disorder. While pathogenic CDK13 variants have been associated with childhood apraxia of speech (CAS), a systematic characterisation of communication has not been conducted. Here we examined speech, language, non-verbal communication skills, social behaviour and health and development in 41 individuals with CDK13-related disorder from 10 countries (male = 22, median-age 7 years 1 month, range 1–25 years; 33 novel). Most participants used augmentative and alternative communication (AAC) in early childhood (24/41). CAS was common (14/22). Performance varied widely across intellectual ability, social behaviour and expressive language skills, with participants ranging from within average through to the severely impaired range. Receptive language was significantly stronger than expressive language ability. Social motivation was a relative strength. In terms of a broader health phenotype, a quarter had one or more of: renal, urogenital, musculoskeletal, and cardiac malformations, vision impairment, ear infections and/or sleep disturbance. All had gross and fine motor impairments (41/41). Other conditions included mild-moderate intellectual disability (16/22) and autism (7/41). No genotype-phenotype correlations were found. Recognition of CAS, a rare speech disorder, is required to ensure appropriately targeted therapy. The high prevalence of speech and language impairment underscores the importance of tailored speech therapy, particularly early access to AAC supports.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Lollipop chart of CDK13 missense variants in this cohort.
Fig. 2: The Vineland Adaptive Behaviour Scales domain scores of participants (n = 36) with c.2525 A > G, p.Asn842Ser missense variants (n = 15) and other pathogenic variants (n = 21).
Fig. 3: Social behaviour domains on the social responsiveness scale second edition (T scores) (n = 27).
Fig. 4: Motor speech disorders in assessed participants (n = 22).

Similar content being viewed by others

Data availability

The datasets generated and analysed during this study are not publicly available because participants have not given permission for data to be made public but may be requested from the corresponding author (A.T.M) who could go back to the participants to request data sharing. Genotypic data were submitted to Decipher (https://decipher.sanger.ac.uk/).

Change history

References

  1. Colas P. Cyclin-dependent kinases and rare developmental disorders. Orphanet J Rare Dis. 2020;15:1–14.

    Article  Google Scholar 

  2. Kohoutek J, Blazek D. Cyclin K goes with Cdk12 and Cdk13. Cell Div. 2012;7:1–10.

    Article  Google Scholar 

  3. Nováková M, Hampl M, Vrábel D, Procházka J, Petrezselyová S, Procházková M, et al. Mouse model of congenital heart defects, dysmorphic facial features and intellectual developmental disorders as a result of non-functional CDK13. Front Cell Dev Biol. 2019:155. https://doi.org/10.3389/fcell.2019.00155.

  4. Sifrim A, Hitz M-P, Wilsdon A, Breckpot J, Al Turki SH, Thienpont B, et al. Distinct genetic architectures for syndromic and nonsyndromic congenital heart defects identified by exome sequencing. Nat Genet. 2016;48:1060–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Bostwick BL, McLean S, Posey JE, Streff HE, Gripp KW, Blesson A, et al. Phenotypic and molecular characterisation of CDK13-related congenital heart defects, dysmorphic facial features and intellectual developmental disorders. Genome Med. 2017;9:1–9.

    Article  Google Scholar 

  6. van den Akker W, Brummelman I, Martis L, Timmermans R, Pfundt R, Kleefstra T, et al. De novo variants in CDK13 associated with syndromic ID/DD: molecular and clinical delineation of 15 individuals and a further review. Clin Genet. 2018;93:1000–7.

    Article  PubMed  Google Scholar 

  7. Uehara T, Takenouchi T, Kosaki R, Kurosawa K, Mizuno S, Kosaki K. Redefining the phenotypic spectrum of de novo heterozygous CDK13 variants: three patients without cardiac defects. Eur J Med Genet. 2018;61:243–7.

    Article  PubMed  Google Scholar 

  8. Hamilton MJ, Caswell RC, Canham N, Cole T, Firth HV, Foulds N, et al. Heterozygous mutations affecting the protein kinase domain of CDK13 cause a syndromic form of developmental delay and intellectual disability. J Med Genet. 2018;55:28–38.

    Article  CAS  PubMed  Google Scholar 

  9. Carneiro TN, Krepischi AC, Costa SS, da Silva IT, Vianna-Morgante AM, Valieris R, et al. Utility of trio-based exome sequencing in the elucidation of the genetic basis of isolated syndromic intellectual disability: illustrative cases. Application Clin Genet. 2018;11:93.

    Article  CAS  Google Scholar 

  10. Trinh J, Kandaswamy KK, Werber M, Weiss ME, Oprea G, Kishore S, et al. Novel pathogenic variants and multiple molecular diagnoses in neurodevelopmental disorders. J neurodevelopmental Disord. 2019;11:1–6.

    Article  Google Scholar 

  11. Yakubov R, Ayman A, Kremer AK, van den Akker M. One-month-old girl presenting with pseudohypoaldosteronism leading to the diagnosis of CDK13-related disorder: a case report and review of the literature. J Med Case Rep. 2019;13:1–5.

    Article  Google Scholar 

  12. Wang T, Hoekzema K, Vecchio D, Wu H, Sulovari A, Coe BP, et al. Large-scale targeted sequencing identifies risk genes for neurodevelopmental disorders. Nat Commun. 2020;11:1–13.

    Google Scholar 

  13. Hildebrand MS, Jackson VE, Scerri TS, Van Reyk O, Coleman M, Braden RO, et al. Severe childhood speech disorder: gene discovery highlights transcriptional dysregulation. Neurology. 2020;94:e2148–e67.

    Article  PubMed  Google Scholar 

  14. Rouxel F, Relator R, Kerkhof J, McConkey H, Levy M, Dias P, et al. CDK13-related disorder: Report of a series of 18 previously unpublished individuals and description of an epigenetic signature. Genet Med. 2022;24:1096–107.

  15. Braden RO, Amor DJ, Fisher SE, Mei C, Myers CT, Mefford H, et al. Severe speech impairment is a distinguishing feature of FOXP1‐related disorder. Developmental Med Child Neurol. 2021;63:1417–26.

    Article  Google Scholar 

  16. Morgan A, Braden R, Wong MM, Colin E, Amor D, Liégeois F, et al. Speech and language deficits are central to SETBP1 haploinsufficiency disorder. Eur J Hum Genet. 2021;29:1216–25.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Morison LD, Braden RO, Amor DJ, Brignell A, van Bon BW, Morgan AT. Social motivation a relative strength in DYRK1A syndrome on a background of significant speech and language impairments. Eur J Hum Genet. 2022;30:800–11.

  18. St John M, Amor DJ, Morgan AT. Speech and language development and genotype–phenotype correlation in 49 individuals with KAT6A syndrome. Am J Med Genet Part A. 2022;188:3389–400.

    Article  Google Scholar 

  19. Sparrow SS, Cicchetti DV, Balla DA. Vineland adaptive behavior scales Vineland-II: survey forms manual: Pearson Minneapolis, MN; 2005.

  20. Sparrow SS, Cicchetti DV, Saulnier CA. Vineland-3: Vineland adaptive behavior scales. London: Psychological Corporation; 2016.

  21. Wetherby AM, Prizant BM. Communication and symbolic behavior scales: developmental profile. Baltimore: Paul H Brookes; 2002.

  22. Bishop DV. The Children’s communication checklist. London: Psychological Corporation; 2003.

  23. Constantino JN, Gruber CP. Social responsiveness scale: SRS-2. Torrance, CA: Western psychological services; 2012.

  24. Association AP. Diagnostic and statistical manual of mental disorders: DSM-5. Washington, DC: American Psychiatric Association; 2013.

  25. Brignell A, Chenausky KV, Song H, Zhu J, Suo C, Morgan AT. Communication interventions for autism spectrum disorder in minimally verbal children. Cochrane Database Syst Rev. 2018.

  26. Sigafoos J, Arthur-Kelly M, Butterfield N. Enhancing everyday communication for children with disabilities. Baltimore: Paul H Brookes Publishing; 2006.

  27. Dodd B, Zhu H, Crosbie S, Holm A, Ozanne A. Diagnostic evaluation of articulation and phonology (DEAP). London: Psychology Corporation; 2002.

  28. O’Brian S, Packman A, Onslow M, O’Brian N. Measurement of stuttering in adults. J Speech, Lang, Hearing Res. 2004;47:1081–7.

    Article  Google Scholar 

  29. ASHA. Childhood apraxia of speech Rockville, MD: American speech-language-hearing association; 2007. Available from: https://www2.asha.org/articlesummary.aspx?id=8589947136.

  30. Mei C, Fedorenko E, Amor DJ, Boys A, Hoeflin C, Carew P, et al. Deep phenotyping of speech and language skills in individuals with 16p11. 2 deletion. Eur J Hum Genet. 2018;26:676–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Morison LD, Meffert E, Stampfer M, Steiner-Wilke I, Vollmer B, Schulze K, et al. In-depth characterisation of a cohort of individuals with missense and loss-of-function variants disrupting FOXP2. J Med Genet. 2022. https://doi.org/10.1136/jmg-2022-108734.

  32. Duffy JR. Motor speech disorders: substrates, differential diagnosis, and management second edition. St. Louis, Missouri: Elsevier Mosby; 2005.

  33. McLeod S, Harrison LJ, McCormack J. The intelligibility in context scale: Validity and reliability of a subjective rating measure. J Speech Lang Hear Res. 2012;5-648–56.

  34. Pados BF, Thoyre SM, Park J. Age‐based norm‐reference values for the child oral and motor proficiency scale. Acta Paediatrica. 2018;107:1427–32.

    Article  PubMed  Google Scholar 

  35. Reid SM, Johnson HM, Reddihough DS. The Drooling Impact Scale: a measure of the impact of drooling in children with developmental disabilities. Developmental Med Child Neurol. 2010;52:e23–e8.

    Article  Google Scholar 

  36. Robbins J, Klee T. Clinical assessment of oropharyngeal motor development in young children. J Speech Hearing Disord. 1987;52:271–7.

    Article  CAS  PubMed  Google Scholar 

  37. Yoss K. Editor developmental apraxia of speech in children: familial patterns and behavioral characteristics. ASHA north central regional conference, Minneapolis; 1975.

  38. Morley ME. The development and disorders of speech in childhood. Austin, TX: Churchill Livingstone; 1972.

  39. Ekelman BL, Aram DM. Syntactic findings in developmental verbal apraxia. J Commun Disord. 1983;16:237–50.

    Article  CAS  PubMed  Google Scholar 

  40. Branson D, Demchak M. The use of augmentative and alternative communication methods with infants and toddlers with disabilities: a research review. Augmentative Alternative Commun. 2009;25:274–86.

    Article  Google Scholar 

  41. Walters C, Sevcik RA, Romski M. Spoken vocabulary outcomes of toddlers with developmental delay after parent-implemented augmented language intervention. Am J Speech-Lang Pathol. 2021;30:1023–37.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Binger C, Light J. The morphology and syntax of individuals who use AAC: research review and implications for effective practice. Augmentative Alternative Commun. 2008;24:123–38.

    Article  Google Scholar 

  43. lacono T, Mirenda P, Beukelman D. Comparison of unimodal and multimodal AAC techniques for children with intellectual disabilities. Augmentative Alternative Commun. 1993;9:83–94.

    Article  Google Scholar 

  44. Atlas THP. CDK13 The Human Protein Atlasn.d. Available from: http://www.proteinatlas.org/ENSG00000065883-CDK13/brain.

  45. Schmahmann JD, Sherman JC. The cerebellar cognitive affective syndrome. Brain: J Neurol. 1998;121:561–79.

    Article  Google Scholar 

  46. Morgan AT, Liégeois F, Liederkerke C, Vogel AP, Hayward R, Harkness W, et al. Role of cerebellum in fine speech control in childhood: persistent dysarthria after surgical treatment for posterior fossa tumour. Brain Lang. 2011;117:69–76.

    Article  CAS  PubMed  Google Scholar 

  47. Luders E, Kurth F, Pigdon L, Conti-Ramsden G, Reilly S, Morgan AT. Atypical callosal morphology in children with speech sound disorder. Neuroscience 2017;367:211–8.

    Article  CAS  PubMed  Google Scholar 

  48. Kaspi A, Hildebrand MS, Jackson VE, Braden R, van Reyk O, Howell T, et al. Genetic aetiologies for childhood speech disorder: novel pathways co-expressed during brain development. Mol Psychiatry. 2022. https://doi.org/10.1038/s41380-022-01764-8.

  49. Thurm A, Farmer C, Salzman E, Lord C, Bishop S. State of the field: differentiating intellectual disability from autism spectrum disorder. Front Psychiatry. 2019:526. https://doi.org/10.3389/fpsyt.2019.00526.

  50. Bonuck K, Battino R, Barresi I, McGrath K. Sleep problem screening of young children by speech-language pathologists: a mixed-methods feasibility study. Autism Developmental Lang Impairments. 2021;6: https://doi.org/10.1177/23969415211035066.

    Article  Google Scholar 

Download references

Acknowledgements

Sincere thanks to the children, families and clinicians who took part in this project.

Funding

This work was supported by a National Health and Medical Research Council (NHMRC) Centre of Research Excellence in Speech and Language Neurobiology (CRE-SLANG) #1116976 awarded to A.T.M.; NHMRC Practitioner Fellowship #1105008 awarded to A.T.M., and an NHMRC Investigator grant #1195955 awarded to A.T.M. This work is also supported by the Victorian Government’s Operational Infrastructure Support Program.

Author information

Authors and Affiliations

  1. Speech and Language, Murdoch Children’s Research Institute, Melbourne, VIC, Australia

    Lottie D. Morison, Olivia van Reyk, Elana Forbes, David J. Amor & Angela T. Morgan

  2. School of Psychological Sciences, Monash University, Melbourne, VIC, Australia

    Elana Forbes

  3. Génétique Clinique, Départment de Génétique Médicale, Maladies Rares et Médecine Personnalisée, CHU Montpellier, Montpellier University, Centre de Référence Anomalies du Développement SOOR, Montpellier, France

    Flavien Rouxel & David Geneviève

  4. Centre de Référence Anomalies du Développment et Syndromes Malformatifs, FHU TRANSLAD, CHU Dijon, Dijon, France

    Laurence Faivre

  5. Genetics of Developmental Disorders, INSERM – Bourgogne Franche-Comté Univeristy, Dijon, France

    Laurence Faivre

  6. Cancer Council Victoria, Melbourne, VIC, Australia

    Fiona Bruinsma

  7. Service de génétique médicale, CHU Nantes, 9 quai Moncousu, Nantes, France

    Marie Vincent

  8. Unit of Medical Genetics, CHU La Réunion, Saint Pierre, France

    Marie-Line Jacquemont

  9. Lucile Packard Children’s Hospital, Stanford Children’s Health, Palo Alto, CA, USA

    Natalie L. Dykzeul

  10. Department of Paediatrics, The University of Melbourne, Melbourne, VIC, Australia

    David J. Amor

  11. The Royal Children’s Hospital, Melbourne, VIC, Australia

    David J. Amor & Angela T. Morgan

  12. Department of Audiology and Speech Pathology, The University of Melbourne, Melbourne, VIC, Australia

    Angela T. Morgan

Authors
  1. Lottie D. Morison
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Olivia van Reyk
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elana Forbes
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Flavien Rouxel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Laurence Faivre
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fiona Bruinsma
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Marie Vincent
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Marie-Line Jacquemont
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Natalie L. Dykzeul
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. David Geneviève
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. David J. Amor
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Angela T. Morgan
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

LDM: generated data, analysed data, interpreted data, wrote manuscript. OV: generated data, analysed data, interpreted data, revised manuscript. EF: analysed data, interpreted data, revised manuscript. FR: generated data, analysed data, revised manuscript. LF: generated data, analysed data, revised manuscript. FB: generated data, analysed data, revised manuscript. MV: generated data, analysed data, revised manuscript. MJ: generated data, analysed data, revised manuscript. NLD: generated data, analysed data, revised manuscript. DG: generated data, analysed data, revised manuscript. DJA: generated data, analysed data, interpreted data, revised manuscript. ATM: designed and conceptualised study, directed project, generated data, analysed data, interpreted data, wrote manuscript.

Corresponding author

Correspondence to Angela T. Morgan.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethics approval

Ethics approval was obtained from the Royal Children’s Hospital, Melbourne, Human Research Ethics Committee (HREC 37353A). Adult participants and caregivers of child participants provided informed consent to participate in the study and for results of this study to be published.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Morison, L.D., van Reyk, O., Forbes, E. et al. CDK13-related disorder: a deep characterization of speech and language abilities and addition of 33 novel cases. Eur J Hum Genet 31, 793–804 (2023). https://doi.org/10.1038/s41431-022-01275-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41431-022-01275-8

This article is cited by

Search

Advanced search

Quick links